Icon times
Navin Fluorine International Ltd | Q4FY21 Earnings Conference call Highlights

Navin Fluorine International Ltd | Q4FY21 Earnings Conference call Highlights

Published on 22 May 2021 Views 207 Comments 1

Covid Overview

  • Plant operations in Surat & Dewas & project activities are running smoothly despite covid related disruptions.
  • Continuous contact with customers, vendors, suppliers to ensure that operations are running smoothly.
  • Planning Onsite vaccination drives at all sites for employees & their family members.

Key Business Highlights for Q4FY21 & FY21

  • Work on HPP & NPP projects in Dahej is continuing in full swing. HPP project might be delayed by a quarter due to 2nd wave of Covid-19.
  • Divested 49% stake in JV2 of Rs. 65.1 crores & gave up the rights on legal land at Dahej for Rs. 7.9 crores. – Gain of Rs. 31.39 crores
  • Gave up the leasehold rights of the land at Dahej to the subsidiary ‘Navin Fluorine Advanced Science Ltd’ & gained Rs. 34.8 Crores.
  • Consolidated basis – net cash position – Rs. 600 crores
  • Prudent use of capital – improved operating return on capital to almost 31%
  • Net operating cash flow from operating activities – Rs. 296 crores improved by Rs. 140 crores as compared to last year – strong improvement in operations

Financial performance highlights

  • Delivered strong Q4FY21 results in which operating revenue was up by 22% to Rs. 324 crores as against Rs. 265 crores in Q4FY20.
  • EBITDA was up by 25% to Rs. 84 crores (26% margin) for Q4FY21 as against 67 crores in Q4FY20.
  • Operating PBT for Q4FY21 was up by 29% to 73 crores (23% margin) as against Rs. 57 crores in Q4FY20.
  • This performance was primarily driven by a growth in Specialty & CRAMS segment.
  • For FY21 standalone basis, operating revenue was at Rs. 1133 crores recording growth of 11% on YoY basis.
  • Standalone Operating EBITDA of Rs. 311 crores for FY21 as against Rs. 261 crores in FY20 with growth of 19% YoY basis.
  • Operating PBT of Rs. 269 crores with growth of 19% on YoY basis for FY21.
  • All this performance was recorded in spite of all the covid restrictions in 1st quarter of FY21.
  • For FY21 standalone, Net revenue from operations of Rs. 1133 crores as against Rs. 1022 crores in FY20, growth of about 11%.
  • Operating EBITDA (standalone basis) stood at Rs. 311 crores (27.4% margin) for FY21 as against Rs. 261 crores in FY20 with growth of 19% YoY basis.
  • Increase in operating EBITDA is due to better performance in high value businesses & revival of legacy businesses towards 2nd half of the year.
  • Operating PBT (standalone basis) was up by 19% and stood at Rs. 269 (24% margin) crores for FY21 as against Rs. 225 crores in FY20.
  • PAT (standalone basis) stood at Rs. 299 crores (26% margin) in FY21 as against Rs. 400 crores in FY20.
  • Robust performance of the company further strengthened the balance sheet & cashflows.

Segment-wise highlights

  • For Q4FY21, high value business grew by 31% & legacy business grew by 10%
  • Specialty business registered growth of 26% whereas CRAMS business registered a growth of 40% for Q4FY21.
  • Overall growth has been driven by high value businesses since good performance growth of 32% in high value businesses to Rs. 732 crores for FY21 YoY basis
  • High Value business now contributes 65% of total revenue for FY21.
  • Specialty business for FY21 stood at Rs. 453 crores witnessed a growth of 19% YoY.
  • Business has shown strong growth driven by mix of new customers, new product & market share gain.
  • Focus in on introducing new products by leveraging R&D capabilities & deep fluorination expertise & building new capacities for existing as well as new products.
  • For FY21, CRAMS business has displayed strong sales with growth of 62% to Rs. 279 crores YoY. This strong performance is driven by new customer acquisition & repeat business from existing customers.
  • Company is looking forward to good project flows for this business from new & existing innovators.
  • Cost improvement measures are taken for repeat business in FY22 leading to better operating efficiencies.
  • Legacy business of Refrigerant gas & inorganic fluorides has shown positive momentum due to new customer signups & demand recovery from the end user industry.
  • For FY21, legacy business revenue was down by 14% YoY to 401 cores & for Q4 revenue grew by 10% to Rs. 117 crores YoY due to demand normalizing
  • Inorganic Fluorides business was down by 7% on YoY basis for FY21 to Rs. 193 crores but for Q4 it recorded good YoY growth of 16% to Rs. 59 crores.
  • Segment’s performance improved QoQ supported by capacity enhancement & recovery of end user industries like          stainless steel & glass.
  • In this particular segment, growth will be driven by new customer additions in exports.
  • Refrigerant business was down by 20% in FY21 on YoY basis to Rs. 208 crores & for Q4 it showed marginal growth of 4% to Rs. 58 crores.
  • Trade & service sectors along with exports have registered strong demand in the quarter. Demand was also enhanced by addition of new customers in international market.
  • On standalone basis, High value business registered a growth of 32% while legacy was lowered by 14% due to reduced demand in the 1st half of the year.
  • In legacy business, performance of inorganic fluorides improved substantially during 2nd half of the year as business registered a marginal revenue de-growth of 7% to Rs. Rs. 193 crores. 
  • Refrigerant business took more time to recover as its revenue showed a de-growth of 20% to Rs. 208 crores for FY21.
  • Specialty business grew by 19% to Rs. 453 crores in FY 21 & CRAMS grew by 62% to Rs. 279 crores in FY21.

Gross margin movement issues

Decrease was driven by 2 reasons:

  1. Refrigerant gas – One of the customers of r22 had shut down for one month due to covid restrictions, hence demand in this segment fell which had high margin
  2. Specialty Chemicals – because of product mix – one big product in industrial segment which the company exports – but demand fell due to supply chain issues in US – container was stuck in Suez Canal issue & on Agro side – increase in demand for product with lower margin.
  3. Impact of raw material on industrial side – Specialty chemeicals – some solvent had up ticked but due to contracted price – increased cost could not be passed on – overall impact minimum on gross margin.
  • These 3-4 issues responsible for dip in gross margin. Overall margin issue is a temporary issue & normalization is hoped to be seen with time.

About various segments:

CRAMS

  • Consistent growth in % terms can’t be witnessed – but business trajectory is on positive side reason of which is acquiring new customers & delivering good business to existing ones.
  • CRAMS have cGMP compliance for capacity building with expect decent utilization for over next 2 years.
  • CRAMS business has got new clients with 25 around new projects.
  • For specialty business & CRAMS business, there is no significant impact of raw material cost inflation on the company’s product, there is clear pass through of prices.
  • Company is currently working on Total re-branding of CRAMS business & will be launched in FY21-22

Specialty Chemicals

  • Great growth in specialty chemicals is expected in next year through de-bottlenecking projects.
  • Not any large brownfield projects planned but de-bottlenecking projects are helping in cost savings & to increase capacities.

 

 

Refrigerant Business

  • Refrigerant business was very high margin business in domestic market but due to shutdown restrictions, it saw a dip but is compensated by identification & development of newer opportunities in CRAMS & specialty chemicals.
  • The reason for slight decline in revenues for Refrigerant business was that trade market was shut in Q1FY21. Hence no sale of R22 in trade market.

Inorganic Fluorides

  • No Significant change in trajectory in next 4 quarters & incremental growth seen for this segment due to changes in end user industry.
  • No significant investment planned for inorganic segment.
  • The reason for slight decline in revenues for Inorganic Fluorides was that sale of Inorganic products in end user industries was very low in Q1FY21 & customers plants were closed.

Current Projects

  • De-bottlenecking projects are continuously done by the company – 4 projects are currently going on in Surat. This is done to map new products or increase the volume of existing products.
  • Company is planning to setup an innovation center abroad which will focus on developing new products as well as on developing new applications since number of new opportunities are available – company is of the view that some opportunities can be grabbed through partnerships.
  • Capacity expansion project for HPP - Completely new greenfield investment in Dahej – plant will start functioning toward the end of FY22 or beginning of FY23 – Phase 1 is complete.

Company outlook

  • Number of new products in pipeline- CRAMS & specialty chemicals.
  • Good opportunities on HPP – company is currently working on them.
  • Run-rate across various segments is slightly higher than the Previous year.
  • Quality of projects have significantly improved – 1st company in the eastern hemisphere that customers are working with on new molecules.
  • Growth of the company was driven by both agro-chemicals as well as by pharmaceuticals. (strong momentum on both agro side & pharma side)
  • Good opportunities are available currently for the company across different segments– operating team is working on them which will be taken up to the board later.
  • Due to HPP Contract- Reinforcement of Trust, there is Technology arbitrage - Positive Momentum is expected in CRAMS, Specialty & HPP – customers are comfortable in approaching the company with more projects – complex as well as value-added projects.
  • Even after the recent departures of CEO & CFO, company’s performance is not hit & is heading in right direct.
  • Mostly investment will now happen in Dahej in next 5 to 6 years- greenfield project has to be set up.

Concluding remark by the company:

  • Company is of the view that business will benefit a lot in coming years with a strong growth momentum. Addition of new customers & products will help to mitigate the risk & company’s expertise in fluorine chemicals will scale up the business sustainably in a profitable manner in next few years.

 

Attachments
File Name
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs 7499/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

LATEST UPDATE

premium Premium
free Free
Read More

REPORTS


Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya